Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
270 Leser
Artikel bewerten:
(1)

Releaf Dispensary Ltd Announces First UK Medical Cannabis Legal Helpline

NOTTINGHAM, UK / ACCESS Newswire / January 15, 2026 / First of its kind in the UK as medical cannabis patients get on-demand legal support with their prescription

The UK's leading medical cannabis clinic launches the service offering prescribed patients on-demand legal guidance following updated police guidance.

January 15, 2026. Releaf, the UK's fastest-growing medical cannabis clinic, has today announced the launch of Releaf Protect, a first-of-its-kind for UK cannabis patients legal guidance service designed to strengthen patient confidence and protection.

Available to eligible members as part of Releaf+, the most comprehensive subscription plan for cannabis patients, Releaf Protect provides access to a dedicated legal helpline offering practical, situation-specific guidance for issues connected to lawful medical cannabis treatment in the UK.

The launch follows the recent publication of an updated police report last week, which provided new guidance on how officers should approach interactions with legally prescribed medical cannabis patients. While this represents an important step forward for patient clarity, many patients still face uncertainty in high-pressure, real-world situations.

Tim Kirby, CEO of Releaf, said, "Medical cannabis has been legal in the UK for several years, yet patients are still too often left carrying the burden of explaining the law in moments that can feel intimidating or stressful. As the UK's leading medical cannabis healthcare provider, we believe our responsibility doesn't end with prescribing; it extends to ensuring patients feel supported, protected and confident in everyday life. Releaf Protect is a meaningful step towards closing that gap, offering practical, responsible support at the moments it genuinely matters."

The service is intended for specific, active situations, such as workplace disputes and interactions with police or other authorities. It forms part of Releaf's wider commitment to leading innovation in the UK cannabis industry, alongside the Releaf Medical Cannabis Card, providing patients with clear, verifiable evidence of their prescription.

Kirby added, "Releaf continues to lead the industry in patient care and confidence. Our Medical Cannabis Card is uniquely supported by a secure two-factor verification process, enabling third parties to independently confirm a patient's lawful prescription if it is ever challenged. The card and new legal guidance service, combined with our one-of-a-kind technology platform, reflects our ongoing commitment to innovation, building real-world solutions that make medical cannabis safer, clearer and more accessible for patients across the UK."

The legal guidance is provided by Irwin Mitchell, a leading UK law firm with extensive experience advising on regulatory, employment, and public law matters. Releaf does not receive the content of legal advice and does not influence the guidance given, ensuring patients receive independent, situation-specific support when it is needed most.

Together, these initiatives are designed to give prescribed medical cannabis patients greater confidence in everyday situations. By improving clarity, reducing misunderstandings and helping prevent unnecessary escalation, Releaf aims to promote better awareness and understanding of lawful medical cannabis prescriptions across the UK.

[END]
About Releaf

Launched in 2024, Releaf is the UK's fastest-growing and most-trusted* medical cannabis clinic, serving patients through its advanced healthtech platform. With a prescriber base of over 50 specialists, we deliver evidence-based cannabinoid care directly to patients' homes through tailored treatment plans. Integrated with NHS systems, Releaf has transformed access to medicinal cannabis treatment in the UK and is now expanding internationally. *According to Trustpilot and CAC.

For more information contact press@releaf.co.uk or visit www.releaf.co.uk

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Releaf Dispensary Ltd



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/releaf-dispensary-ltd-announces-first-uk-medical-cannabis-legal-helpl-1127453

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.